Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 11/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | RPA1 | P27694 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657904 | 0.80 | TRPV1 (0.46) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL25511207 | 0.76 | PTGS1 (0.46) | KLKB1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL22417059 | 0.75 | KLKB1 (0.58) | KLKB1CARM1RIPK2 | |
| SCHEMBL659101 | 0.75 | TRPV1 (0.42) | KLKB1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL660095 | 0.74 | MAPK14 (0.48) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL658627 | 0.73 | KLKB1 (0.40) | KLKB1KDM4E | |
| SCHEMBL657732 | 0.73 | TRPV1 (0.44) | KLKB1MAPTALDH1A1 | |
| SCHEMBL25541972 | 0.71 | PTGS1 (0.47) | KLKB1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL22417077 | 0.71 | KLKB1 (0.54) | KLKB1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL659074 | 0.71 | EPHX1 (0.40) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | TRPV1, CNR1, CNR2 | KLKB1 4444/4885MAPK13 1876/4885MAPK12 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.